- Home
- FTAI vs RPRX Comparison
FTAI vs RPRX Comparison
Compare FTAI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTAI | RPRX |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 16.2B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FTAI | RPRX |
|---|---|---|
| Price | $176.26 | $39.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $199.00 | $46.00 |
| AVG Volume (30 Days) | 992.6K | ★ 4.3M |
| Earning Date | 10-27-2025 | 11-05-2025 |
| Dividend Yield | 0.79% | ★ 2.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.36 | 1.75 |
| Revenue | $2,344,200,000.00 | ★ $2,349,844,000.00 |
| Revenue This Year | $50.33 | $37.13 |
| Revenue Next Year | $25.31 | $1.48 |
| P/E Ratio | $40.59 | ★ $22.68 |
| Revenue Growth | ★ 51.35 | 3.70 |
| 52 Week Low | $75.06 | $24.05 |
| 52 Week High | $194.36 | $41.24 |
Technical Indicators
Market Signals| Indicator | FTAI | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 57.50 |
| Support Level | $163.65 | $39.24 |
| Resistance Level | $174.67 | $40.50 |
| Average True Range (ATR) | 7.75 | 0.91 |
| MACD | 2.00 | -0.08 |
| Stochastic Oscillator | 98.15 | 76.02 |
Price Performance
Historical ComparisonAbout FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.